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a  b  s  t  r  a  c  t
The  objective  of  this  study  was  to use  probabilistic  sensitivity  analysis  to  evaluate  the  cost-effectiveness  of
using  an on-farm  culture  (OFC)  approach  to the  treatment  of  clinical  mastitis  in  dairy  cows  and  compare
this  to a ‘standard’  treatment  approach.  A  speciﬁc  aim  was  to identify  the herd circumstances  under
which  an OFC  approach  would  be most  likely  to  be cost-effective.  A stochastic  Monte  Carlo  model  was
developed  to simulate  5000  cases  of  clinical  mastitis  at  the  cow  level  and  to  calculate  the  associated  costs
simultaneously  when  treated  according  to 2  different  treatment  protocols;  i)  a ’conventional’  approach
(3 tubes  of  intramammary  antibiotic)  and  ii) an OFC  programme,  whereby  cows  are  treated  according  to
the  results  of  OFC.  Model  parameters  were  taken  from  recent  peer  reviewed  literature  on the  use  of  OFC
prior  to  treatment  of  clinical  mastitis.  Spearman  rank correlation  coefﬁcients  were  used  to  evaluate  the
relationships  between  model  input  values  and  the  estimated  difference  in  cost  between  the  standard  and
OFC  treatment  protocols.  The  simulation  analyses  revealed  that  both  the difference  in the bacteriological
cure  rate  due  to a delay  in  treatment  when  using  OFC  and  the proportion  of  Gram-positive  cases  that  occur
on  a dairy  unit  would  have  a fundamental  impact  on  whether  OFC  would  be cost-effective.  The  results  of
this study  illustrated  that  an  OFC  approach  for the treatment  of clinical  mastitis  would  probably  not  be
cost-effective  in  many  circumstances,  in particular,  not  those  in  which  Gram-positive  pathogens  were
responsible  for more  than  20%  of  all clinical  cases.  The  results  highlight  an  ethical  dilemma  surrounding
reduced  use  of  antimicrobials  for clinical  mastitis  since  it may  be associated  with  ﬁnancial  losses  and
poorer  cow  welfare  in  many  instances.
© 2017  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Mastitis is one of the most prevalent and costly diseases affect-
ng dairy cows worldwide. The cost of clinical mastitis is made up of
direct’ costs, such as the cost of drugs, discarded milk and increased
abour and ‘indirect’ costs, such as reduced future production,
ncreased culling and increased the risk of disease transmission to
erd mates. The overall cost of a case of clinical mastitis has been
hown to be highly variable (Huijps et al., 2008; Green et al., 2009)
nd most inﬂuenced by ‘indirect’ costs (Kossaibati and Esslemont,
000; Huijps et al., 2008; Down et al., 2013).Not only is mastitis important in terms of the economics, but
he treatment and prevention of mastitis is widely reported as the
ost common reason for antimicrobial drug use on dairy farms
∗ Corresponding author.
E-mail address: peter.down@nottingham.ac.uk (P.M. Down).
ttp://dx.doi.org/10.1016/j.prevetmed.2017.07.006
167-5877/© 2017 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
(Pol and Ruegg, 2007; Thomson et al., 2008; González et al., 2010).
There is increasing pressure on the agricultural sector to reduce
antimicrobial drug usage due to fears over antimicrobial resistance
(AMR) (O’Neill, 2015) and the way  in which antimicrobial drugs
are applied with respect to the treatment of mastitis is, therefore, a
sensible target. Conventionally, all cases of clinical mastitis would
receive a course of antimicrobial agents but an alternative approach
is the selective treatment of cases according to the results of an on-
farm culture (OFC) system. With the OFC system, only non-severe
cases that yield a Gram-positive or mixed-culture are treated with
antimicrobial drugs resulting in many cases of clinical mastitis not
being treated at all (Lago et al., 2011a). This was demonstrated
recently in a study performed in 8 herds based in Minnesota, Wis-
consin and Ontario, which reported that 51% of cows enrolled in
the OFC group received antimicrobial drugs as opposed to 100%
of the cows enrolled in the conventional group. The same study
reported no statistical differences between the two groups with
respect to the bacteriological cure risk, the time taken to clinical
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ure, new intramammary infection risk, treatment failure risk or
isk of removal from the herd within 21 days (Lago et al., 2011a).
While OFC appears to be effective in reducing antimicrobial drug
sage; little is known about factors inﬂuencing the overall cost-
ffectiveness of this approach and, therefore, the types of herds in
hich it is most likely to be cost-effective. When performing such a
ost-effectiveness analysis, there are inevitably multiple sources of
vidence for parameter estimates and a degree of uncertainty sur-
ounding their true value (Ades et al., 2006). For decision-making
urposes, it is important that cost-effectiveness models are able to
ncorporate multiple sources of evidence and reﬂect uncertainty in
he model outputs (Claxton et al., 2005; Babo Martins and Rushton,
014). An approach to this now widely reported in the human
ealth literature (Briggs et al., 2002; Brown et al., 2006) and increas-
ngly in the veterinary literature (Down et al., 2013; Hudson et al.,
014, 2015) is probabilistic sensitivity analysis (PSA). The main
eature of this technique is that all input parameters are speci-
ed as full probability distributions, rather than point estimates,
o represent the uncertainty surrounding their values. This param-
ter uncertainty is then propagated through the cost-effectiveness
odel so that the resulting imprecision is reﬂected in model out-
uts and inferences made (Briggs et al., 2002).
The purpose of this research was to use probabilistic sensitivity
nalysis to investigate the main factors that inﬂuence the cost-
ffectiveness of an OFC approach to treating clinical mastitis. The
odel used was an adaptation of one reported previously (Down
t al., 2013), with the addition of OFC-speciﬁc parameters based on
revious research (Lago et al., 2011a). A speciﬁc aim was to iden-
ify the herd circumstances under which an OFC approach would
e most likely to be cost-effective.
. Materials and methods
.1. Model structure
A stochastic Monte Carlo model was developed using Open-
UGS 3.2.2 software (Thomas et al., 2006). The model was  used
o simulate a case of clinical mastitis at the cow level and to cal-
ulate the associated costs simultaneously when treated according
o 2 different treatment protocols; i) a ‘conventional’ approach (3
ubes of intramammary antibiotic) and ii) an OFC programme as
escribed by Lago et al. (2011a) in which milk samples taken from
ows with CM were cultured on-farm using the Minnesota Easy
ulture System (University of Minnesota, St. Paul). This on-farm
ilk culture system consisted of a bi-plate, which is a Petri dish
ith two different types of agar: MacConkey agar on one half that
electively grows Gram-negative bacteria and Factor media on the
ther half of the plate that selectively grows Gram-positive bacte-
ia. The plate was placed in an on-farm incubator and incubated
t approximately 37 ◦C for 18–24 h. The next day, the plate was
xamined for bacterial growth and interpreted by herd personnel
nd if bacteria did not grow, the plate was returned to the incubator
nd re-read approximately 18–24 h later. Results for each sample
late were recorded as (1) Gram-positive, when bacteria grew only
n the Factor agar media of the bi-plate; (2) Gram-negative, when
acteria grew only in the MacConkey agar media of the bi-plate;
3) no growth, when bacteria did not grow on either media; or
4) mixed infection when bacteria grew on both media. Quarters
rom which Gram-positive bacteria were isolated or had a mixed
nfection received intramammary antibiotic treatment and if the
n-farm milk culture result was Gram-negative or no growth, the
uarter did not receive intramammary therapy.
The general model structure and assumptions were consistent
rrespective of the treatment protocol applied and was as described
reviously by Down et al. (2013) (Fig. 1). An initial case of clinicalry Medicine 145 (2017) 91–99
mastitis (CM1) could either; i) cure bacteriologically, ii) cure clin-
ically but remain subclinically infected, or iii) fail to cure (either
clinically or bacteriologically). If CM1  failed to cure, then a repeat
treatment (same as initial treatment) would be administered and
the same three outcomes permitted. If CM1  cured bacteriologically,
then the cow could either end the lactation or be culled before
the end of lactation. If CM1  cured clinically but not bacteriologi-
cally, then it could either end the lactation, be culled before the
end of lactation, or have a repeat episode of clinical mastitis (CM2).
CM2  would be treated according to the same protocol as CM1 and
would then follow the same possible outcomes as CM1. A third
clinical recurrence was permitted for subclinically infected cows
(CM3) which were again treated in the same way  as CM1  and CM2.
If the cow remained subclinically infected after CM3  or failed to
cure clinically, then the cow would be culled before the end of lac-
tation. If the cow cured bacteriologically after CM3, then it could
either ﬁnish the lactation or be culled before the end of lactation.
A risk of transmission parameter was included from cows that
remained subclinically infected after CM1  and CM2. This repre-
sented the risk that the infection was transmitted from the infected
cow to one of the other 99 ‘susceptible’ cows in the herd during a
12-week period. The 12-week period was split into 14-day blocks
meaning the infected cow could infect another cow in the herd
every 14-days. If infection did spread to another cow, then it too
would be considered to be infectious during the subsequent 14-
day blocks. For example, if a cow remained subclinically infected
after CM1, and it transmitted an infection to another cow during
the ﬁrst 14-day block, then there would be two  infectious cows at
the start of the second 14-day block, and the susceptible population
would be 98 cows. However, it should be noted that the transmis-
sion parameter would be applicable to herds of different sizes and
the results of the model could be extrapolated to herds of any size.
2.2. Model input parameters
The model was parameterized with distributions based on
existing literature and current commercial data where possible
(Table 1). All parameter inputs were speciﬁed as uniform distri-
butions with the purpose of simulating a wide variety of different
scenarios without making assumptions as to which was the most
likely. The distribution ranges were based on the literature wher-
ever possible, but if only point estimates were available, then
plausible ranges were added to the point estimate. The input
parameters were the same as used in the study by Down et al.
(2013), with the addition of some OFC-speciﬁc parameters based
on the study by Lago et al. (2011a).
Economic parameter distributions included the cost of drugs,
labour, milk withdrawal and loss of milk production, culling and
death (Table 1). The cost of labour is subject to large variation
quoted in the literature. For this reason a wide distribution was
assigned to the hourly cost of labour with the upper limit taken
from Huijps et al. (2008). The total time taken to treat each case
of CM was assigned a distribution centred on the ﬁgures given
by Steeneveld et al. (2011) surrounded by an additional variation
of +/− 10 minutes. The total cost of labour was the product of the
hourly rate and the total treatment time.
The length of milk withdrawal after CM was  deﬁned by a distri-
bution based on the commonly used medicines in the UK and the
amount of milk being discarded each day was taken from a plausible
milk yield distribution (Table 1). The distribution deﬁned for milk
price was  taken from DairyCo (2012a) and based on the average UK
milk price over the last 12 months (range: lowest price and highest
price). The cost of milk production was based on Huijps et al. (2008)
and assigned a uniform distribution to reﬂect the variability in the
ﬁgure (Table 2).
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Fig. 1. Schematic representation of the treatment model. Complete cure = bacteriological and clinical cure. Clinical cure = non-bacteriological cure but clinical cure. No
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pure  = no bacteriological or clinical cure. Cull = culled sometime within the remaind
ase  received initially. RT = risk of transmission. CM1  = initial case of clinical mastiti
The calculation of total yield loss following a case of CM was
ased on the herd 305 day yield, the parity of the animal and
he stage of lactation in which the infection occurred (Table 1).
he distributions governing the percentage of total loss in 305 day
ilk yield were based on Hagnestam et al. (2007). The proportion
f cases occurring at each stage postpartum and the propor-
ion of cases affecting multiparous cows versus primiparous cows
as governed by distributions based on Steeneveld et al. (2011)
Table 1). The cost associated with the total loss in milk yield was
alculated according to the total loss in earnings (i.e. the quantity
f milk multiplied by the milk price) minus the savings made in
eed costs (i.e. the quantity of milk loss multiplied by the cost of
roduction). All distributions are provided in Table 1.
The cost of culling a cow within the remainder of the current lac-
ation was taken from a uniform distribution based on Huijps et al.
2008) and Kossaibati and Esslemont (2000), which included the
laughter value and replacement costs, with an appropriate range
dded to reﬂect the variability of this parameter (Table 1). The cost
f the death of an individual was based on current UK average sales
rices for freshly calved cows and heifers (DairyCo, 2012b) which
ould be required to replace the dead cow in addition to the cost
f carcass disposal (Table 1).
The original calculations were made in Great British Pounds (£)
nd converted to US Dollars ($) using the exchange rate of 1.45 $/£
http://www.xe.com/currencyconverter/; accessed 15th February
016).
.3. On-farm culture speciﬁc input parametersThe OFC-speciﬁc input parameters comprised distributions
eﬂecting changes to the bacteriological cure risk, the proportion of
ulture-positive cases, the time taken to set-up and read the culture
lates and the cost of a plate. The distribution for the reduction inhe current lactation. Extended treatment = a repeat of the same treatment that the
 = ﬁrst clinical ﬂare-up. CM3  = secon clinical ﬂare-up.
bacteriological cure risk associated with the OFC protocol was uni-
form (−0.22 to 0), meaning the maximum reduction possible was
22%, and the minimum was  0. The middle value of 11% was  the
non-signiﬁcant effect size reported by Lago et al. (2011a) which
was the overall reduction in bacteriological cure risk in cases of
clinical mastitis treated with the OFC protocol compared to cases
treated with the conventional approach. The distribution specify-
ing the ‘herd-level’ proportion of Gram-positive cases was uniform
(0.1–0.9), meaning the lowest proportion was  10% of cases with a
Gram-positive culture and the highest proportion was 90%. This dis-
tribution reﬂects the wide spread of values identiﬁed in the study
by Lago et al. (2011a). There were no published ﬁgures for the cost
of the biplate used in the study or the time taken to set-up and
evaluate the culture results so plausible ranges were estimated as
($1.45–2.03) and (30–60 min) respectively. The distributions used
for all other input parameters are listed in Table 1.
2.4. Model simulation
The model was  used to simulate 5000 cases of CM1  for each
treatment protocol which was sufﬁcient for all combinations of
treatment scenarios and other input parameters to be effectively
investigated so that dependencies could be evaluated. At each
model-iteration, a value was selected at random from within the
ranges speciﬁed for each input parameter, independent of each
other, and the associated costs calculated. The parameter values
and overall cost were stored for each model-iteration and were
used for subsequent analysis. The outcome of interest was  the
difference in overall cost between the two  protocols which was
calculated at each model-iteration by subtracting the cost of the
OFC approach from the cost of the conventional approach. There-
fore, a positive value would indicate that the conventional approach
was more cost-effective and a negative value would indicate that
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Table 1
Probability distributions applicable to both treatment protocols and relevant sources of literature on which they are based where applicable.
Input parameters Upper and lower limits
of uniform distribution
Source
Probability of bacteriological cure (0.40,0.80) a, b, c, d, e, f, g, h
Probability of bacteriological cure after extended tx (0.30,0.90) Based upon Steeneveld et al. (2011)
Decrease in probability of bacteriological cure1 Based upon Steeneveld et al. (2011)
Parity ≥2 (−0.15,−0.05)
Days in milk ≥60 days (−0.15,−0.05)
Cow is systemically ill (−0.25,−0.15)
SCC 200,000–500,000 cells/mL at most recent recording (−0.15,−0.05)
SCC >500,000 cells/mL at most recent recording (−0.25,−0.15)
Repeated case (>1st case in current lactation) (−0.25,−0.15)
Probability of being culled for bacteriologically noncured cases Based upon Bar et al. (2008)
Initial case (0,0.32)
Following ﬁrst ﬂare-up (CM2) (0.04,0.36)
Probability of being culled for completely cured cases Based upon Bar et al. (2008)
Initial case (0.04,0.06)
Following ﬁrst ﬂare-up (CM2) (0.10,0.20)
Following second ﬂare-up (CM3) (0.20,0.30)
Probability of death for nonclinical cured cases (0.04,0.06) Based upon Bar et al. (2008)
Probability of drying-off quarter for nonclinical cured cases (0.94,0.96) Based upon Steeneveld et al. (2011)
Probability of being culled for cows with dried off quarters (0.27,0.39) Based upon Steeneveld et al. (2011)
Increase in all culling probabilities when cow is systemically ill (0.05,0.15) Based upon Steeneveld et al. (2011)
Probability of clinical ﬂare-up for bacteriologically noncured cases (0.05,0.12) m,  n, o
Probability of transmission after CM1  and CM2  (0.002,0.25) van den Borne et al. (2010)
Proportional yield loss j, k
Case  in 1st or 2nd month of lactation (0.07,0.09) j, k, l
Case  between months 3 and 6 (0.03,0.08)
Case after month 6 (0,0.04)
Parity ≥2 (0,0.02)
305d Yield (Kg) (7000,10,000) Author2
Milk withdrawal (d) (5.00,9.00) Based upon commonly used preparations in the UK
Daily  milk discard (Kg) (5.00,50,00) Author2
Value of discarded milk ($/Kg) (0.33,0.39) DairyCo (2012a)
Cost of milk production ($/Kg) (0.043,0.145) Based upon Huijps et al. (2008)
Treatment Time (hr) (0.53,0.87) Based upon Steeneveld et al. (2011)
Cost of labour ($/hr) (1.45,23.01) Based upon Huijps et al. (2008)
Cost of drugs ($) (8.10,10.11) Based upon estimate of current retail price of
commonly used preparations in the UK
Cost  of cull ($) (174,1044) Based upon Huijps et al. (2008),  Kossaibati and
Esslemont (2000)
Cost of death ($) (1740,2900) DairyCo (2012b)
a Based upon McDougall (1998), b Based upon McDougall (2003), c Based upon Oliver et al. (2003), d Based upon Wraight (2003), e Based upon Sérieys et al. (2005), f Based
upon  McDougall et al. (2007), g Based upon Bradley and Green (2009), h Based upon Sol et al. (2000), j Based upon Gröhn et al. (2004), kBased upon Schukken et al. (2009), l
Based  upon Hagnestam et al. (2007), m Based upon Swinkels et al. (2005a), n Based upon Swinkels et al. (2005b), o Based upon Döpfer et al. (1999).
1 The value selected from this distribution was  subtracted from the value selected from the bacteriological cure distribution.
2 Author – where there was  no relevant literature identiﬁed on which to base the parameter, distributions were based on biologically plausible values instead.
Table 2
On-farm culture speciﬁc model input parameters and the relevant sources of literature on which they were based where applicable.
Input parameters Upper and lower limits of uniform distribution Source
Proportion of Gram-positive cases (0.10,0.90) Based upon Lago et al. (2011a)
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wReduction in bacteriological cure risk (−0.22,0.00) 
Cost of plate ($) (1.45,2.03) 
Culture time (h) (0.30.1.00) 
he OFC protocol was more cost-effective. The distribution specify-
ng the herd-level proportion of Gram-positive cases would govern
hether the case treated according to the OFC protocol was Gram-
ositive (or mixed infection) and, therefore, treated with antibiotics
r Gram-negative (or no growth) and, therefore, not treated with
ntibiotics. In this way, the impact of the proportion of Gram-
ositive cases on the overall cost-effectiveness of the OFC protocol
ould be assessed.
.5. Data analysis
Spearman rank correlation coefﬁcients were calculated to
xplore the univariate associations between model input param-
ters and the difference in cost between the conventional and OFC
reatment protocols. The strength and direction of the relationships
ere evaluated using the Spearman rank rho () value. The outcomeBased upon Lago et al. (2011a)
Based upon current retail price
Expert opinion
variable of speciﬁc interest was  the difference in cost between the
two treatment protocols. However, additional model parameters
were included to provide further insight into where cost differences
arose. These were the cost of antimicrobial drugs, the difference in
time taken to treat each case, the difference in milk withdrawal
period and the difference in the risk of transmission.
Descriptive analysis was performed to identify scenarios in
which the OFC approach was  most cost-effective. To facilitate
this, the 5000 simulated cases were sub-divided into three groups
according to the magnitude of reduction in bacteriological cure risk
associated with the OFC protocol as compared with the conven-
tional approach; i) large difference (LD) group (17–22% reduction),
ii) moderate difference (MD) group (5–17% reduction) and iii) small
difference (SD) group (0–5% reduction). The difference in cost-
effectiveness between the conventional and OFC protocols was
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Fig. 2. Difference in cost between conventional and on-farm culture protocols. A positive difference in cost indicates that the on-farm culture protocol cost more than the
conventional protocol.
Fig. 3. Difference in cost between conventional and on-farm culture protocols when the
cost  indicates that the on-farm culture protocol cost more than the conventional protoco
Table 3
Spearman rank correlation coefﬁcients for on-farm speciﬁc model input parameters
and  the difference in cost between the conventional and on-farm culture treatment
protocols.
Parameter rho
Proportion culture-positive 0.31
Difference in bacteriological cure risk −0.28
t
o
3
3
t
t
m
$
w
pCost of plate 0.0062
Culture time 0.02
hen assessed for the different groups and at different proportions
f Gram-positive cases.
. Results
.1. Data analysis
Across all 5000 simulated cases, the conventional protocol was
he most cost-effective 68% of the time. The median cost related
o a case treated with the conventional protocol was  $529, and the
edian cost related to a case treated with the OFC protocol was554. The maximum difference in cost between the two  protocols
as $328 with a median of $28.
The Spearman rank correlation coefﬁcients for the OFC-speciﬁc
arameters are shown in Table 3. The difference in cost betweenre was  a small difference (SD) in bacteriological cure risk. A positive difference in
l.
the two  protocols was most closely related to the difference in bac-
teriological cure risk and the proportion of Gram-positive cases. As
the difference in bacteriological cure risk and proportion of Gram-
positive cases increased, the difference in overall cost became
higher, making the OFC protocol less cost-effective than the con-
ventional protocol. Both the cost of the biplate and the time taken
to set-up and evaluate the biplate had a negligible relationship
with the cost-effectiveness of the OFC protocol as measured by the
Spearman rank correlation coefﬁcients (Table 3).
With respect to the model input parameters common to both
protocols, those signiﬁcantly associated with the difference in cost
were the difference in the milk withdrawal period (rho = 0.75), dif-
ference in the cost of drugs (rho = 0.61), difference in the time taken
to treat the cow (and culture) (rho = 0.61) and the difference in the
risk of transmission (rho = 0.51).
3.2. Scenario and sensitivity analysis
The median difference in cost between the two protocols was
plotted against the proportion of Gram-positive cases, and this indi-
cated that the proportion of Gram-positive cases would need to
be less than 12% for the OFC protocol to be more cost-effective
than the conventional protocol (Fig. 2). When the proportion of
Gram-positive cases increased to 50%, the OFC protocol was  on
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Fig. 4. Difference in cost between conventional and on-farm culture protocols when there was a moderate difference (MD) in bacteriological cure risk. A positive difference
in  cost indicates that the on-farm culture protocol cost more than the conventional protocol.
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big. 5. Difference in cost between conventional and on-farm culture protocols wh
ost  indicates that the on-farm culture protocol cost more than the conventional pr
verage $42 more expensive per case than the conventional proto-
ol. However, the difference in cost between the treatment groups
as sensitive to the underlying bacteriological cure risk of Gram-
ositive cases. When clinical mastitis was subdivided according to
hether the difference in bacteriological cure risk was  small (SD)
edium (MD) or large (LD) the difference in the cost-effectiveness
f the treatments was as follows. The OFC protocol was  more cost-
ffective than the conventional protocol when the proportion of
ram-positive cases was less than 47% in the SD group (Fig. 3) and
ess than 21% in the MD  group (Fig. 4). The OFC protocol was  never
ore cost-effective than the conventional protocol for cases in the
D group (Fig. 5). Therefore, the underlying bacteriological cure risk
as a key parameter determining relative cost-effectiveness of the
reatment approaches.. Discussion
The simulation analyses revealed that both the difference in the
acteriological cure risk due to a delay in treatment and the pro-re was  a large difference (LD) in bacteriological cure risk. A positive difference in
l.
portion of Gram-positive cases that occur on a dairy unit will have
a fundamental impact on whether OFC will be cost-effective. There
has undoubtedly been a shift in the aetiology of clinical mastitis
towards environmental pathogens, with coliforms and no-growths
frequently reported as accounting for approximately 50% of all clin-
ical mastitis culture results (Bradley and Green, 2001; Bradley et al.,
2007; Breen et al., 2009) as was  the case in the study by Lago et al.
(2011a). On this basis, it would be fair to assume that most dairy
herds would expect to treat approximately 50% of clinical masti-
tis cases with antimicrobial drugs if utilizing an OFC approach. The
reduction in bacteriological cure risk associated with OFC  is more
difﬁcult to predict as there is very little published data on the extent
to which cure is reduced when basing treatment decisions on the
results of OFC. However, a reduction of some degree is possible
given the 24 h delay in initiating antimicrobial treatment for the
Gram-positive cases and the potential for Gram-positive cases to be
incorrectly diagnosed as Gram-negative and therefore not treated,
as was the case in 14% of the cases not treated with antibiotics in
the study by Lago et al. (2011a). Given the results of this research,
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urther work to quantify any likely reduction in bacteriological cure
isk that is associated with OFC is critical, if the cost-effectiveness
nd welfare implications of OFC are to be established.
One of the aims stated by the authors of the original OFC studies
Lago et al., 2011a,b) was to use their results to evaluate the over-
ll cost-beneﬁt of using an OFC system, but to date, no data have
een published. In a decision tree analysis used to evaluate the eco-
omic impact of different durations of intramammary treatment
or the ﬁrst case of mild or moderate clinical mastitis occurring
n early lactation, it was  found that OFC was only likely to offer
conomic beneﬁts in herds using extended-duration therapy with-
ut regard for pathogen diagnosis (Pinzón-Sánchez et al., 2011).
he results of this study serve to illustrate that an OFC approach
or the treatment of clinical mastitis would probably not be cost-
ffective in many circumstances, in particular, not those in which
ram-positive pathogens represent more than 20% of all clinical
ases. Since Streptococcus uberis and Staphylococcus aureus remain
ommon mastitis pathogens on dairy units in many countries, the
ost-effectiveness of OFC should be carefully scrutinised in these
ircumstances.
While OFC will reduce total antimicrobial drug usage on farm,
he effect on cow health and welfare and overall dairy farm prof-
tability should also be considered. The assertion that there is no
mportant reduction in bacteriological cure from delayed treatment
f Gram-positive pathogens is fragile and requires substantially
ore research with sufﬁcient power to detect small differences
n effect size. In the study by Lago et al. (2011a), statistical anal-
sis revealed a non-signiﬁcant difference of 11% in bacteriological
ure risk between the conventional and OFC groups. In that study,
he sample size used meant that a difference ≥14% would have
een needed between groups to detect the difference as being ‘sig-
iﬁcant’ (Lago et al., 2011a) and it, therefore, remains uncertain
hether there is a true difference in bacteriological cure between
roups. The sensitivity analysis in the current study suggests that
 difference in cure risk of less than 14% could certainly deter-
ine whether OFC is cost-effective and, therefore, larger studies
o ascertain this true difference are needed.
Signiﬁcant differences were reported in the pathogen-speciﬁc
acteriological cure risk in the study by Lago et al. (2011a), partic-
larly with respect to Staphylococcus aureus.  While the reason for
hese differences is unknown, it is possible that the reduction in
acteriological cure risk associated with OFC is a result of delayed
reatment as was hypothesised by Lago et al. (2011a) and has been
eported in a previous study (Hillerton and Semmens, 1999). Given
he importance of this parameter, future research should include
athogen-speciﬁc differences in bacteriological cure risk, when
reatment is delayed by using OFC.
In the current study, the overall proportion of Gram-positive
ases was also shown to be related to the likelihood of cost-
ffectiveness of an OFC treatment programme. The proportion of
ram-positive cases was shown to be highly variable in the study
y Lago et al. (2011a) in which the proportion of quarter cases
eceiving intramammary antibiotic treatment as a consequence
f assignment to the OFC protocol ranged from 31%–89% in the
ight study herds. In the current study, the overall proportion of
ram-positive cases had to be less than 12% (depending on bac-
eriological cure risk) for OFC to be more cost-effective than the
onventional protocol. By this measure, OFC would not have been
ost-effective in any of the herds in the study by Lago et al. (2011a).
owever, when cases were grouped according to the difference in
acteriological cure risk, OFC would be cost-effective when the pro-
ortion of Gram-positive cases was less than 47% in the SD group
nd less than 21% in the MD  group. The OFC approach would, there-
ore, be most suitable for herds in which Gram-negative pathogens
re responsible for most clinical mastitis and where the treatment
f cows using an OFC approach results in a minimal reduction inry Medicine 145 (2017) 91–99 97
the bacteriological cure risk. In practice, it is possible to assess the
proportion of Gram-positive cases on a unit, and this will inform
decision making on the likely cost-beneﬁt of OFC.
There may  be a balance to be struck between reducing antimi-
crobial usage and possible deleterious effects in terms of cow
welfare and farm ﬁnances; would the extra cost incurred by adopt-
ing an OFC approach be considered a price worth paying if it results
in a reduction in antibiotic drug usage on dairy farms by 25%, as was
estimated by Lago et al. (2011a)? If, for societal reasons, this was
considered to be a price worth paying, there is also an issue of who
should bear the cost. Whilst difﬁcult, it is perhaps time such debates
became transparent given the increasing pressure on antimicrobial
drug usage and the potential risks posed by antimicrobial resis-
tant bacteria. In the absence of legal jurisdiction, it is incumbent
on those advising on animal health and welfare to ensure that
the adoption of new technologies, such as OFC, are undertaken in
light of comprehensive, transparent welfare and cost-effectiveness
assessments.
Whilst the overall likelihood of cost-effectiveness was affected
mostly by the proportion of Gram-positive cases and the difference
in bacteriological cure risk, the parameters within the model that
had the largest impact on the difference in cost were the differ-
ence in milk-withdrawal period, the difference in the cost of drugs,
the difference in culture and treatment time and the difference in
risk of transmission. Clearly, OFC would be expected to reduce the
amount of milk withdrawn from sale and the amount of money
spent on drugs because a proportion of the cows would not receive
any antimicrobial treatment and would therefore not incur any
statutory milk withhold upon resolution of clinical signs. This is
in agreement with Lago et al. (2011a) that reported a reduction in
milk withdrawal period (5.2 days v 5.9 days) and quantity of antimi-
crobial drug usage (51% of OFC cases treated v 100% of conventional
cases treated) associated with OFC. The increase in labour required
to acquire milk samples from clinical mastitis cases in an aseptic
manner and plate out for culture is perhaps harder to assess and is
likely to represent a cost not only in terms of the time taken, but
also the opportunity cost incurred as a result of the herdsman being
unable to perform other duties as a result. The distribution used in
this study of 30–60 min  is, therefore, likely to be a realistic estimate
for most circumstances. The large impact that transmission could
have on the cost of a case of clinical mastitis has been reported pre-
viously (Down et al., 2013) and it is not surprising therefore that
it was closely related to the difference in cost between the con-
ventional and OFC approaches also. While the risk would clearly be
inﬂuenced by herd management and pathogen-speciﬁc factors; it
could also be affected by any delay in treatment and differences
in bacteriological cure risk associated with OFC resulting in an
increased risk of transmission. This again would need to be assessed
at the herd level. It is worth noting that milk price had very little
impact on the difference in cost between the two protocols. This is
unsurprising given the poor correlation between milk price and the
cost of a case of CM that has been reported previously (Down et al.,
2013) and serves to demonstrate that whilst important in terms
of overall farm proﬁtability (Smith and Thanassoulis, 2015), milk
price plays a minor role in terms of the cost of CM.
There will inevitably be some unknown parameters in any cost-
effectiveness model (Buxton et al., 1997) and these parameters
will have a degree of uncertainty surrounding their true value.
PSA permits the incorporation of this parameter uncertainty which
is subsequently propagated through the model and is therefore
reﬂected in the model outputs. It is widely considered to be an
implementation of Bayesian statistics because all parameters have
a probability distribution which is a distinguishing feature of the
Bayesian approach (O’Hagan, 2003; Boshuizen and van Baal, 2009).
One of the key advantages of the Bayesian approach in medicine is
that it removes the reliance on signiﬁcance testing and the use of
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rbitrary thresholds of ‘signiﬁcance’ (Gurrin et al., 2000; Greenland
nd Poole, 2013) meaning the clinician is free to make their own
udgement as to what is clinically ‘signiﬁcant’ according to the
egree of uncertainty they are comfortable with. In this study, the
SA allowed an evaluation of the parameters likely to be important
n determining the cost-effectiveness of the OFC approach and has
ighlighted that more research is needed in this ﬁeld before the
echnique can be recommended on a widespread basis.
. Conclusions
The results of this study indicate that the proportion of Gram-
ositive cases and the difference in bacteriological cure risk
etween the two treatment approaches has the greatest impact on
he probability that an OFC approach would be more cost-effective
han a conventional approach for the treatment of clinical masti-
is. The OFC approach appears to be suitable for herds in which
ram-negative pathogens are responsible for most clinical masti-
is and where the treatment of cows according to the results of an
FC approach results in minimal reductions in the bacteriological
ure risk. These results suggest that OFC will probably not be cost-
ffective for many herds and that OFC should, therefore, only be
dopted after careful consideration of the predominant pathogens
resent in each herd and an honest discussion about the uncertainty
urrounding its overall cost-effectiveness.
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